Arlington cybersecurity start-up ThreatConnect said Tuesday that it has raised $16 million from investors, led by the corporate venture capital arm of SAP’s North American subsidiary in Rockville. The next morning just down the road in Sterling, Va., a similarly-named start-up called ThreatQuotient said it raised $10.2 million, led by prolific technology investor New Enterprise Associates. A few weeks ago Arlington-based Trustar announced a $2 million in seed funding.
Jeff Carroll inherited the DNA mutation that causes Huntington’s disease. It means that in a decade or two, he’ll lose control over his body and slowly go mad, just like his mother.
That’s the reason Carroll, 38, says he’d be in favor of gene editing embryos. He says the idea of correcting DNA errors in the next generation has no “ick factor” for him at all. “I have no compunctions about it,” says Carroll, who is a neuroscientist at Western Washington University, in Bellingham. “I am saying, please, please do mess with our DNA.”
Supports K@W’s Innovation Content Pfizer Inc. raked in more than $12.4 billion in revenue in both 2007 and 2008 from just one drug, Lipitor. The cholesterol-lowering mega-blockbuster accounted for more than a quarter of the pharmaceutical giant’s total revenue in those years.
But those golden days couldn’t last.
The D.C.-based venture capital firm Revolution Growth is bringing on additional talent.
The firm, founded by AOL co-founder Steve Case, Monumental Sports & Entertainment’s CEO and owner Ted Leonsis, and Donn Davis, announced the hiring of four new vice presidents Tuesday to help spur additional investments and push for a greater return on its portfolio.
DATE: Wednesday, December 9, 2015
LOCATION: Montgomery County Department of Economic Development, 111 Rockville Pike, Suite 800, Rockville, MD 20850
The FDA Technology Transfer program seeks to advance the development and commercialization of inventions that result from regulatory science research and development conducted at the FDA. Regulatory Science can be defined as the science of developing new tools and technologies to assess the safety, efficacy, quality, and performance of FDA-regulated products. Technology Transfer tools used by the FDA Technology Transfer Program are the same tools used by Federal Agencies and FDA technology transfer-related policies are similar to the policies of the NIH and CDC. However, the range of technologies developed at the FDA is more diverse- a reflection of the FDA’s role in ensuring the safety of food, drugs, biologics, medical devices, tobacco, and veterinary medicines.
In this day and age, you can easily share photos through Dropbox, notes in Evernote, or spreadsheets via Google Drive with anyone. But good luck helping two doctors at two different hospitals to see the same patient records online. Instead, when a patient goes to a medical center for the first time, they often have to repeat tests they’ve undergone before—such as a computerized tomography (CT) scan, which uses X-ray technology to produce cross-sectional images of the body.
Thursday, December 10, 2015 from 8:00 AM to 10:00 AM, bwtech@UMBC
Senator Mikulski is retiring.
Governor Hogan is just getting started.
Who’s the next champion of Maryland’s life sciences sector?
Please join We Work For Health (WWFH) Maryland and the University of Maryland Baltimore County (UMBC) as we explore how to develop Maryland’s next generation of elected leaders to foster medical innovation and grow our regional bio-economy.
Over breakfast, members of the biotechnology and pharmaceutical industry, government, labor, and academic community will discuss the importance of identifying and cultivating medical innovation leaders to help address our challenges and make the most of our
The Maryland Technology Development Corp. (TEDCO) is bringing in an industry veteran to turn its $106 million Maryland Venture Fund into a regional leader in venture funding.
Andy Jones, an entrepreneur and venture capitalist, joined TEDCO on Monday as managing director of the Maryland Venture Fund. Jones’ prime task will be to elevate the fund from a supporting investor to a leader in venture capital that drives more money to local companies.
No one wants to be the flavor of the month – except during that month.
That’s the danger for today’s healthcare startups and their leadership as they look to find the right investors and partners. Our prediction: Alternative investing paths such as venture philanthropy and corporate venture capital will become even more prominent than they are today (and that’s pretty big, considering the results of the survey Lake Whillans commissioned from MedCity News).
Thursday, December 10, 2015 | 6:30pm-8:30pm, Johns Hopkins East, 1101 East 33rd Street, Baltimore, Maryland 21218 | 3rd Floor Conference
Learn how to secure National Institutes of Health SBIR/STTRs for your high-tech bio-innovation.
Dr. Doswell lead JUICE Money wins for high-tech minority companies and HBCUs such as:
